Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A genomic classifier called PAM50 may help doctors decide which prostate cancer patients benefit from adding hormone therapy to salvage radiation. In a phase 3 trial, patients with "luminal B" tumors saw dramatically better outcomes when androgen deprivation therapy (ADT) was added — while non-luminal B patients saw little benefit. This could help spare some patients from unnecessary treatment and its side effects.
When prostate cancer returns after surgery — signaled by a rising PSA — doctors often turn to salvage radiation, sometimes paired with hormone therapy (ADT). But not every patient benefits equally from ADT, and it comes with real side effects. New data presented at the ASTRO 2026 annual meeting suggest a genomic tool called PAM50 could help sort out who actually needs it.
Researchers analyzed tumor samples from 709 patients enrolled in the phase 3 NRG/RTOG 0534 SPPORT trial. PAM50 classified tumors as either "luminal B" or "non-luminal B." Luminal B tumors are more proliferative and androgen-driven — which may explain why they respond better to ADT. Patients with luminal B status who received ADT alongside radiation saw a 31% absolute improvement in 5-year freedom from progression, compared to just 10% in non-luminal B patients.
By the Numbers:
Why it matters: If validated, PAM50 could become a practical tool to personalize salvage treatment — intensifying therapy for those most likely to benefit while sparing others from hormone therapy they don't need.
